January 17, 2025 04:12 PM ESTUpdated 04:35 PM

Sage sues Biogen days after $469M buyout offer

Max Bayer

Pharma Reporter

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger neuroscience pharma company.

The full …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage sues Biogen days after $469M buyout offer

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Ozempic makes list for next round of Medicare drug price negotiations

What Trump's CMS can and can't change with the second round of drug price negotiations

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

HHS blasts Boehringer's drug price case, reveals new details on Jardiance talks

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

Sage sues Biogen days after $469M buyout offer

Ozempic makes list for next round of Medicare drug price negotiations

What Trump's CMS can and can't change with the second round of drug price negotiations

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

HHS blasts Boehringer's drug price case, reveals new details on Jardiance talks